Beyond Access vs. Protection in Trials of Innovative Therapies

+ See all authors and affiliations

Science  14 May 2010:
Vol. 328, Issue 5980, pp. 829-830
DOI: 10.1126/science.1189369

You are currently viewing the summary.

View Full Text


Over the past decade, researchers have initiated innovative, early-phase, clinical trials, including the first-ever testing in humans of cell therapies for myocardial infarction (1), as well as transplantation of embryo-derived tissues for spinal cord repair (2). The next decade promises more initiatives involving first-in-human trials of innovative therapeutic strategies (3).